1 result
  • xadago

    (safinamide mesylate)
    MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.
    XADAGO is indicated as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease experiencing "off" episodes.